New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
05:41 EDTBIND, RHHBYBIND Therapeutics, Roche collaborate on discovery of novel nanomedicines
BIND Therapeutics (BIND) announced that it has entered into a research agreement with Roche (RHHBY) to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND’s Accurin technology with Roche’s proprietary therapeutic payloads and targeting ligands.
News For BIND;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 5, 2015
13:58 EDTRHHBYSome European stocks still look appealing amid Greek uncertainty, Barron's says
Subscribe for More Information
July 1, 2015
08:46 EDTRHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
June 23, 2015
09:14 EDTBINDOn The Fly: Pre-market Movers
Subscribe for More Information
07:31 EDTBINDBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
June 22, 2015
10:16 EDTBINDBIND Therapeutics names Andrew Hirsch as president and CEO
BIND Therapeutics announced that Andrew Hirsch has been appointed president and CEO of the company. Hirsch had been serving in the role on an acting basis since March. Hirsch has also been elected to BIND’s Board of Directors. “After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the company’s growth,” said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use